Iovance Biotherapeutics, Inc. Announces Management Changes
May 19, 2021 at 09:18 pm IST
Share
On May 18, 2021, Maria Fardis, the Chief Executive Officer (“CEO”) of Iovance Biotherapeutics, Inc., notified the Company that she will be resigning as President, CEO and a director of the Company to pursue other opportunities. The Company will immediately begin a search for a successor. In the meantime, effective upon Dr. Fardis’ departure, the Board of Directors of the Company will appoint Frederick G. Vogt, Ph.D., the Company’s current General Counsel, as the Company’s interim President and CEO.
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
IOVANCE BIOTHERAPEUTICS, INC. 
